Table 3.
Characteristics of primary endpoints in clinical trials with non-severe patients
| Continuous (N=68) | Binary (N=255) | Ordinal (N=71) | Time-to-event (N=70) | Other (N=16) | |
|---|---|---|---|---|---|
| Time frame | |||||
| ≤14 days | 35 (51.5%) | 79 (31.0%) | 39 (54.9%) | 11 (15.7%) | 5 (31.3%) |
| 15–30 days | 26 (38.2%) | 144 (56.5%) | 30 (42.3%) | 44 (62.9%) | 8 (50.0%) |
| >30 days | 7 (10.3%) | 32 (12.5%) | 2 (2.8%) | 15 (21.4%) | 3 (18.8%) |
| Evaluation of clinical course | |||||
| Improvement | - | 61 (23.9%) | - | 53 (75.7%) | - |
| Worsening | - | 135 (52.9%) | - | 10 (14.3%) | - |
| Unknown | - | 59 (23.1%) | - | 7 (10.0%) | - |
| Sample size (trials with 1 arma) | |||||
| (N=24) | (N=57) | (N=9) | (N=16) | (N=3) | |
| Mean (SD) | 82.6 (99.8) | 579.9 (634.8) | 290.2 (219.3) | 262.3 (303.4) | 183.3 (104.1) |
| Median (IQR) | 60 (47.5, 60) | 300 (136, 1000) | 250 (90, 466) | 150 (121, 202.5) | 150 (125, 225) |
| Sample size (trials with 2 armsa) | |||||
| (N=27) | (N=150) | (N=44) | (N=33) | (N=9) | |
| Mean (SD) | 730.5 (1675.1) | 777.2 (1107.2) | 336.8 (238.4) | 464.6 (553.7) | 1513.6 (2021.3) |
| Median (IQR) | 250 (101, 284) | 400 (131.3, 1144.5) | 300 (109.5, 480) | 278 (100, 554) | 1444 (100, 1728) |
| Sample size (trials with ≥3 armsa) | |||||
| (N=17) | (N=48) | (N=18) | (N=21) | (N=4) | |
| Mean (SD) | 530.9 (990.9) | 1225.2 (2347.2) | 1481.1 (3228.3) | 1034.2 (2223.6) | 1042.5 (1431.5) |
| Median (IQR) | 200 (200, 200) | 320 (200, 1480) | 120 (120, 283.5) | 320 (200, 676) | 475 (247.5, 1270) |
aA single drug with multiple doses that was placed under the same “Arm” in interventions was considered as one arm
SD standard deviation, IQR interquartile range